Related references
Note: Only part of the references are listed.netmeta: An R Package for Network Meta-Analysis Using Frequentist Methods
Sara Balduzzi et al.
JOURNAL OF STATISTICAL SOFTWARE (2023)
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
M. R. Bishop et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma
F. L. Locke et al.
NEW ENGLAND JOURNAL OF MEDICINE (2022)
CAR T cells as a second-line therapy for large B-cell lymphoma: a paradigm shift?
Jason Westin et al.
BLOOD (2022)
Lisocabtagene maraleucel versus standard of care with salvage chemotherapy followed by autologous stem cell transplantation as second-line treatment in patients with relapsed or refractory large B-cell lymphoma (TRANSFORM): results from an interim analysis of an open-label, randomised, phase 3 trial
Manali Kamdar et al.
LANCET (2022)
Cytokine release syndrome and neurological event costs in lisocabtagene maraleucel-treated patients in the TRANSCEND NHL 001 trial
Jeremy S. Abramson et al.
BLOOD ADVANCES (2021)
Matching-adjusted indirect treatment comparison of liso-cel versus axi-cel in relapsed or refractory large B cell lymphoma
David G. Maloney et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
Polatuzumab Vedotin in Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Laurie H. Sehn et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)
Ruth Pettengell et al.
BRITISH JOURNAL OF HAEMATOLOGY (2020)
A Systematic Review of the Clinical Efficacy of Treatments in Relapsed or Refractory Diffuse Large B Cell Lymphoma
Per-Olof Thuresson et al.
ADVANCES IN THERAPY (2020)
Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)
Franck Morschhauser et al.
LANCET HAEMATOLOGY (2019)
Emerging therapies for the treatment of relapsed or refractory diffuse large B cell lymphoma
R. Skrabek et al.
CURRENT ONCOLOGY (2019)
Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma
Fang Bao et al.
CANCER GENE THERAPY (2019)
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Stephen J. Schuster et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Progression-free survival at 24 months (PFS24) and subsequent outcome for patients with diffuse large B-cell lymphoma (DLBCL) enrolled on randomized clinical trials
M. J. Maurer et al.
ANNALS OF ONCOLOGY (2018)
Advances in the GRADE approach to rate the certainty in estimates from a network meta-analysis
Romina Brignardello-Petersen et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2018)
Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience
Loretta J. Nastoupil et al.
BLOOD (2018)
Systematic review of therapy used in relapsed or refractory diffuse large B-cell lymphoma and follicular lymphoma
Aaron Galaznik et al.
FUTURE SCIENCE OA (2018)
Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma
Nam H. Dang et al.
BRITISH JOURNAL OF HAEMATOLOGY (2018)
Ofatumumab Versus Rituximab Salvage Chemoimmunotherapy in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: The ORCHARRD Study
Gustaaf W. van Imhoff et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Phase 1 Results of ZUMA-1: A Multicenter Study of KTE-C19 Anti-CD19 CAR T Cell Therapy in Refractory Aggressive Lymphoma
Frederick L. Locke et al.
MOLECULAR THERAPY (2017)
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
S. S. Neelapu et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Review of Autologous Stem Cell Transplantation in Lymphoma
Umar Zahid et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2017)
Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study
Michael Crump et al.
BLOOD (2017)
A randomized phase II study of standard-dose versus high-dose rituximab with BEAM in autologous stem cell transplantation for relapsed aggressive B-cell non-hodgkin lymphomas: long term results
Samer A. Srour et al.
BRITISH JOURNAL OF HAEMATOLOGY (2017)
A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
Myron S. Czuczman et al.
CLINICAL CANCER RESEARCH (2017)
Phase 2 study of panobinostat with or without rituximab in relapsed diffuse large B-cell lymphoma
Sarit E. Assouline et al.
BLOOD (2016)
2016 US Lymphoid Malignancy Statistics by World Health Organization Subtypes
Lauren R. Teras et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2016)
Diffuse large B-cell lymphoma: R-CHOP failure-what to do?
Bertrand Coiffier et al.
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2016)
Rituximab Treatment Strategy for Patients with Diffuse Large B-Cell Lymphoma after First-Line Therapy: A Systematic Review and Meta-Analysis
Yuan-Rong Ren et al.
CHINESE MEDICAL JOURNAL (2015)
Dacetuzumab plus rituximab, ifosfamide, carboplatin and etoposide as salvage therapy for patients with diffuse large B-cell lymphoma relapsing after rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone: a randomized, double-blind, placebo-controlled phase 2b trial
Luis Fayad et al.
LEUKEMIA & LYMPHOMA (2015)
Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement
David Moher et al.
SYSTEMATIC REVIEWS (2015)
Phase III Randomized Study of Rituximab/Carmustine, Etoposide, Cytarabine, and Melphalan (BEAM) Compared With Iodine-131 Tositumomab/BEAM With Autologous Hematopoietic Cell Transplantation for Relapsed Diffuse Large B-Cell Lymphoma: Results From the BMT CTN 0401 Trial
Julie M. Vose et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
A randomized study comparing yttrium-90 ibritumomab tiuxetan (Zevalin) and high-dose BEAM chemotherapy versus BEAM alone as the conditioning regimen before autologous stem cell transplantation in patients with aggressive lymphoma
Avichai Shimoni et al.
CANCER (2012)
Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lymphoma: a phase 3, multicentre, open-label, randomised trial
Ruth Pettengell et al.
LANCET ONCOLOGY (2012)
Consistency and inconsistency in network meta-analysis: model estimation using multivariate meta-regression
Ian R. White et al.
RESEARCH SYNTHESIS METHODS (2012)
Graphical methods and numerical summaries for presenting results from multiple-treatment meta-analysis: an overview and tutorial
Georgia Salanti et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
GRADE guidelines: 3. Rating the quality of evidence
Howard Balshem et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2011)
Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Jonathan W. Friedberg
HEMATOLOGY-AMERICAN SOCIETY HEMATOLOGY EDUCATION PROGRAM (2011)
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Julian P. T. Higgins et al.
BMJ-BRITISH MEDICAL JOURNAL (2011)
ESHAP Versus Rituximab-ESHAP in Frail Patients With Refractory Diffuse Large B-Cell Lymphoma
Agustin Aviles et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2010)
Gemcitabine and treatment of diffuse large B-cell lymphoma in relapsed or refractory elderly patients: A prospective randomized trial in Algeria
Mourad Aribi et al.
JOURNAL OF CANCER RESEARCH AND THERAPEUTICS (2010)
Salvage Regimens With Autologous Transplantation for Relapsed Large B-Cell Lymphoma in the Rituximab Era
Christian Gisselbrecht et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Cost-Effectiveness of the Addition of Rituximab to CHOP Chemotherapy in First-Line Treatment for Diffuse Large B-Cell Lymphoma in a Population-Based Observational Cohort in British Columbia, Canada
Karissa M. Johnston et al.
VALUE IN HEALTH (2010)
Rituximab improves the treatment results of DHAP-VIM-DHAP and ASCT in relapsed/progressive aggressive CD20+ NHL:: a prospective randomized HOVON trial
Edo Vellenga et al.
BLOOD (2008)
Evaluation of networks of randomized trials
Georgia Salanti et al.
STATISTICAL METHODS IN MEDICAL RESEARCH (2008)
Practical methods for incorporating summary time-to-event data into meta-analysis
Jayne F. Tierney et al.
TRIALS (2007)
Rituximab and ICE as second-line therapy before autologous stem cell transplantation for relapsed or primary refractory diffuse large B-cell lymphoma
T Kewalramani et al.
BLOOD (2004)
Ifosfamide, carboplatin, etoposide (ICE)-based second-line chemotherapy for the management of relapsed and refractory aggressive non-Hodgkin's lymphoma
AD Zelenetz et al.
ANNALS OF ONCOLOGY (2003)
CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma.
B Coiffier et al.
NEW ENGLAND JOURNAL OF MEDICINE (2002)
Share Paper
